Balyasny Asset Management LLC Incyte Corp Call Options Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $28.9 Million - $35.4 Million	421,000 Added 1403.33%	451,000 $31 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $741,800 - $1.09 Million	-10,000 Reduced 25.0%	30,000 $3.12 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $11.7 Million - $13.8 Million	-160,000 Reduced 80.0%	40,000 $2.97 Million
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $3.68 Million - $4.44 Million	-50,000 Reduced 20.0%	200,000 $17.7 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $20.8 Million - $25.2 Million	250,000 New	250,000 $20.8 Million

628

198M

766K

476K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.